Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

By Kai Chang, I. Pastan, M. Willingham. 1992

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma (2021, background): “MSLN is initially expressed as a precursor glycoprotein of 71 kDa that is cleaved by the endoprotease furin, thus causing a 31 kDa N-terminal soluble protein, called megakaryocyte potentiating factor (MPF), to be released (Figure 1A) [13].”
Application of Mesothelin Immunostaining in Tumor Diagnosis (2003, background): “Mesothelin is a cell surface antigen that was first described as the antigenic target of the K1 monoclonal antibody that was generated using the OVCAR-3 ovarian cell line as immunogen.(3,5) It is a glycosyl-phosphatidylinositol-linked”
Mesothelin-targeted CAR-T cell therapy for solid tumors (2020, background): “as well as with the normal mesothelium [37].”